Disease Treatments Using Multimeric TNFSF Ligands
Tech ID: 19475 / UC Case 1999-003-0
UCSD researchers have developed an invention useful for:
- augmenting immunity (both cellular and antibodies) against cancer and infectious diseases
- Expanding immune cells (B cells, dendritic cells, macrophages and T cells) in vitro for reinfusion of them or their products
- Immunological testing of immune function. In one embodiment, the invention is a soluble recombinant fusion protein containing multiple CD40 ligands ("CD40L").
This protein affects macrophages and B cells in the same manner as membrane CD40L. The same technology can be applied to produce other members of the TNF family, such as TNF-alpha, FasL, TRAIL, RANKL, 4-1BBL, and others.
The advantages of this new form of CD40L are:
- Versatile - treatment for cancer and infectious disease agents such as HIV and Mycobacterium tuberculosis; vaccines; expanding immune cells; and diagnostic tests of immune function; may have utility in neutralizing autoimmune response in diseases such as lupus or multiple sclerosis.
- Potent - affects macrophages and B cells in the same manner as membrane CD40L.